Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Innovation1 Biotech Inc. incurred convertible notes of $78,695 with two lenders (the "Purchasers") at 8% per annum maturing September 30, 2024.
- Instrument
- convertible notes
- Principal
- $78,695
- Counterparty
- two lenders (the "Purchasers")
- Rate
- 8% per annum
- Maturity
- September 30, 2024
- Event
- incurrence
Exact text from the filing
On September 1, 2023, Innovation1 Biotech Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) with two lenders (the “Purchasers”), pursuant to which the Company issued and sold the Purchasers Original Issue Discount Secured Convertible Promissory Notes in the principal amount of $78,695 (collectively, the “Notes”) for gross proceeds of $66,891.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Innovation1 Biotech Inc. entered into Securities Purchase Agreement with two lenders (the “Purchasers”) valued at principal amount of $78,695 (effective 2023-09-01).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- two lenders (the “Purchasers”)
- Value
- principal amount of $78,695
- Effective
- 2023-09-01
Exact text from the filing
On September 1, 2023, Innovation1 Biotech Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) with two lenders (the “Purchasers”), pursuant to which the Company issued and sold the Purchasers Original Issue Discount Secured Convertible Promissory Notes in the principal amount of $78,695 (collectively, the “Notes”) for gross proceeds of $66,891.
View on SEC.gov